Our research focuses on the discovery of small molecules (compounds), which can disrupt the interaction between MEF2C and DNA. When there is an overexpression of MEF2C it causes a challenging form of blood cancer called immature acute leukemia. Previously, targeting transcription factors such as MEF2C seemed impossible because of their ability to bind to DNA and alter gene expression. Technological advances have made the development of targeted medicines without affecting other cellular functions feasible. We have developed methods to quickly and accurately identify effective compounds in large quantities. After identifying promising compounds, our primary goal is to validate their efficacy and optimize their properties, possibly leading to the development of new patented compounds. This will make drug discovery for immature acute leukemia more efficient and offer potential applications for targeting similar proteins involved in other diseases. This research is crucial in tackling immature acute leukemias without clear treatment protocols. Targeted therapy represents a major leap forward for these patients and offers a more precise approach compared to conventional treatments. This therapy can significantly improve patients’ quality of life by selectively targeting cancer cells and sparing healthy cells. Moreover, its applicability extends beyond leukemia, as MEF2C has been implicated in other cancers and disorders, suggesting broader therapeutic implications. In conclusion, our research promotes health care through scientific knowledge. Besides, it stimulates innovation in the pharmaceutical and biotechnology sectors but also drives economic growth and development.